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 Patients with chronic kidney disease 
(CKD) are at increased risk of throm-
boembolic events; however, anticoagula-
tion in this patient population has always 
presented a challenge to the treating phy-
sician, especially in patients with neph-
rotic syndrome and end-stage renal 
disease. 1 Since its approval in the 1950s 
warfarin remains the standard of care for 
oral anticoagulation: it interferes with the 
synthesis of clotting factors by inhibiting 
the C1 subunit of the vitamin K epoxide 
reductase enzyme complex. Th e elimina-
tion of warfarin relies primarily on its 
liver metabolism through the cytochrome 
P450 pathway. 2 Warfarin has a narrow 
therapeutic range and interacts with a 
variety of commonly used medications 
and dietary factors, especially leafy green 
vegetables. Its use requires close monitor-
ing, and hemorrhage remains its most 
common and feared complication. 
In CKD patients, that risk is increased 
more than twofold. In a recent study, 
patients with severe CKD were found to 
need signifi cantly lower warfarin doses to 
achieve therapeutic anticoagulation, spent 
less time in target international normal-
ized ratio (INR) range, and frequently 
were over-anticoagulated. 1 
 Brodsky  et al. 3 (this issue) describe 
another complication of warfarin therapy, 
extending their previously described 
entity in nine patients with CKD. 4 Warfa-
rin-related nephropathy (WRN), as they 
have termed it, is clinically detected as an 
episode of unexplained acute renal injury 
defi ned as a serum creatinine increase 
greater than 0.3  mg / dl within one week of 
an INR measurement greater than 3.0 in 
a patient being treated with warfarin with-
out clinical evidence of hemorrhage. 
Although previously described cases 
occurred in the setting of CKD, 4 the cur-
rent report suggests that WRN can also 
occur in the general population, with age, 
diabetes mellitus, hypertension, and 
cardiovascular disease being signifi cant 
risk factors. Brodsky  et al. 3 analyzed 
the administrative records of 15,258 
patients who initiated warfarin therapy 
between January 2005 and 2008 at the 
Ohio State University Medical Center. 
WRN occurred in 20.5 % of the entire 
cohort, 33.0 % of the CKD cohort, and 
16.5 % of the non-CKD cohort. One-year 
mortality was 31.1 % in patients with 
WRN versus 18.9 % in patients without 
WRN. A major limitation of this retro-
spective review of administrative records 
was the reliance on medical coding for the 
diagnosis of CKD (ICD-9 codes 585.1 
through 585.5 or 585.9, excluding 585.6). 
Unfortunately, there was no systematic 
examination of urine protein excretion, 
which could well be an independent risk 
factor for overcoagulation associated with 
loss of procoagulant factors in the urine 
and might have allowed better charac-
terization of the actual incidence and 
severity of CKD in patients receiving war-
farin therapy. 
 Th e lack of reported hematuria in the 
setting of WRN despite the presence of 
renal tubular obstruction by red blood 
cells 4 on kidney biopsy is challenging, 
especially if the diagnosis has to be exclu-
sively based on pathology in subjects at 
risk who are already overcoagulated. 4 Th e 
proposed diagnostic criteria for WRN 
include a 0.3 mg / dl increase in serum 
creatinine in patients who have had a 
measured INR greater than 3 within the 
previous week. Th e original description of 
WRN was based on detailed pathologic 
findings on renal biopsy; 4 it would be 
astounding if the prevalence of renal path-
ologic changes were comparable to the 
20.5 % of the 15,258 patients who initiated 
warfarin therapy in the single-center study 
by Brodsky  et al. 3 What is currently lack-
ing is any reasonable estimate of the 
specifi city and sensitivity of the proposed 
diagnostic criteria. 
 Prospective multicenter studies are 
needed to better defi ne the clinical fea-
tures and prevalence of WRN and the 
characteristics of susceptible patients, 
including estimated glomerular fi ltration 
rate (eGFR), urinary protein and albumin 
excretion, quantitative evaluation of 
urinary red blood cells, protein S and C 
deficiency, and so on. Although renal 
biopsies are possible in high-risk antico-
agulated patients with short-term reversal 
of the warfarin eff ect using fresh-frozen 
plasma, renal biopsies cannot be used to 
ascertain the incidence of WRN. One par-
ticular clinical feature that deserves closer 
evaluation is the presence and extent of 
proteinuria, which may alter the coagula-
tion profi le of CKD patients. 5 As  Figure 1 
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shows, the apparent short-term incidence 
rate ratio for WRN is 3.03 when nephrotic 
patients are compared with non-nephrotic 
patients, though ascertainment bias may 
occur when hospital discharge coding is 
used to defi ne nephrotic syndrome with-
out any information about the actual urine 
protein excretion rates. 
 If coagulopathy alone is related to the 
development of WRN, then one might 
expect to fi nd similar cases in the setting of 
coagulopathies or chronic use of other anti-
coagulants. A number of alternatives to war-
farin are under development, including 
direct thrombin inhibitors, such as dabigat-
ran, and direct factor Xa inhibitors. 6 
 Dabigatran has recently been approved 
for reduction of the risk of stroke and 
systemic embolization in patients with 
non-valvular atrial fi brillation and can be 
used at 150  mg twice a day in patients 
with creatinine clearance greater than 
30  ml / min, and 75  mg twice a day for 
patients with 15 – 30  ml / min creatinine 
clearance. Dabigatran is not recom-
mended for patients with creatinine clear-
ance less than 15  ml / min or on dialysis. Its 
mechanisms of action and metabolism are 
diff erent from those of warfarin. It has a 
rapid onset of action and predictable 
pharmacokinetics that allow its use with-
out the need for routine monitoring. 7 It 
would be interesting in the future to see 
whether similar cases of unexplained 
acute kidney injury are reported in the 
setting of dabigatran use. Another area of 
interest would be the incidence of WRN 
in patients who require treatment to an 
INR target of 3.0, such as those with 
mechanical heart valves. 
 Beyond its well-known inhibition of the 
vitamin K-dependent clotting factors, 
warfarin ’ s biologic eff ects on other vitamin 
K-dependent proteins is less well under-
stood. In recent years, two such proteins 
have come to the forefront: matrix Gla 
protein (MGP) and growth arrest-specifi c 
gene 6 (Gas-6) protein. Both proteins have 
been identifi ed as participating in blood 
vessel defense against and repair from 
injury. Th e activation of these proteins 
requires a carboxylation step that is vita-
min K-dependent and hence is inhibited 
by warfarin. 2 While long-term warfarin 
exposure in animal models leads to vas-
cular calcifi cation, and similar chronic 
complications are described in humans as 
tissue necrosis and calciphylaxis, 8 one 
might wonder whether a more acute 
exposure to warfarin may lead to vascular 
damage including glomerular disruption 
and hemorrhage. Unfortunately, the cur-
rent study by Brodsky  et al. 3 was not 
designed to assess the length of exposure 
to warfarin prior to the INR ’ s going above 
3, although they do mention that  “ WRN 
occurs early in the course of warfarin 
therapy. ” 
 The use of warfarin in patients with 
concomitant end-stage renal disease and 
atrial fi brillation was recently found to be 
associated with an increased risk of inci-
dent stroke that appeared to be dose-
dependent and related to increased INR. 9 
The prevalence of atrial fibrillation in 
CKD has recently been highlighted in a 
cross-sectional analysis of the Chronic 
Renal Insuffi  ciency Cohort. 10 Atrial fi bril-
lation was present in 18 % of the study 
population and in more than 25 % of 
the participants older than 70 years. Th is 
prevalence was similar to that reported 
in patients with end-stage renal disease, 
and two to three times greater than that 
in the general population. 10 Th ere was 
no evident association with eGFR strata, 
and proteinuria does not appear to have 
been assessed. In view of the high risk of 
adverse outcomes and challenges 
with coumadin therapy in the CKD 
population, a prospective analysis 
of the incidence and complications 
of atrial ibrillation and the risks 
associated with coumadin therapy is 
sorely needed. 
 Brodsky  et al. 3 have identifi ed another 
potential, serious complication of warfa-
rin therapy in patients with CKD. Beyond 
its consequence in terms of accelerated 
progression of renal disease, WRN seems 
to also be associated with an increased 
risk of death. Given the fact that warfarin 
is prescribed to millions of patients in the 
United States, the public-health implica-
tions of such an entity are tremendous. 
With this report, Brodsky  et al. 3 alert us to 
the importance of even relatively modest 
increases in serum creatinine following an 
elevated INR and suggest vigilance in the 
ascertainment and evaluation of these 
events as they relate to renal damage and 
worsening of CKD. Future reports will 
hopefully confi rm the existence of WRN, 
with better characterization of its features 
and predisposing risk factors. Th e inci-
dence and prevalence, and primary risk 
factors, have to be prospectively defi ned 
with clinical criteria, now that the entity 
has been defined on the pathologic 
level in high-risk patients receiving 
warfarin therapy. 
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 Figure 1  |  Apparent incidence rates of warfarin-related nephropathy in CKD patients with 
nephrotic syndrome and CKD patients without nephrotic syndrome. (Adapted from Table 1 of 
Brodsky  et al. 3 ) 
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 Advanced glycation end products (AGEs) 
are formed in diverse settings, including 
in association with diabetes, aging, 
hypoxia, ischemia – reperfusion injury, 
renal failure, and infl ammation. Exoge-
nous AGEs are thought be absorbed into 
the circulation from reactions between 
sugars and proteins in foods. Indeed, 
AGE content is high in cooked and pro-
cessed foods, especially those rich in pro-
teins, fats, and glucose. Dietary AGEs are 
considered to be similar to endogenous 
AGEs with regard to their pro-oxidant, 
pro infl ammatory, and signaling proper-
ties. Importantly, the kidney is a target 
organ for AGE-mediated damage and 
also the main contributor to increasing 
circulating AGE concentration, since 
clearance of AGEs is reduced when renal 
function declines. 1 The receptor for 
AGEs (RAGE) was fi rst identifi ed as the 
signal trans duction receptor for AGEs. 
Initially, the role of RAGE in renal dys-
function was studied in diabetes; how-
ever, more recently, RAGE also seems to 
play a role in the pathogenesis of renal 
disorders that are not associated with 
diabetes, such as obesity-related glome-
rulopathy, doxorubicin-induced nephro-
pathy, renal amyloidosis, and ischemic 
renal injuries. 2 
 Epidemiological studies indicated that 
obesity is a risk factor for developing end-
stage renal disease. 3 Obesity leads to a 
form of nephropathy characterized by 
glomerulomegaly. Varying degrees of focal 
segmental glomerulosclerosis and podo-
cyte foot process effacement have also 
been documented in obese individuals, 
albeit to a lesser degree than those 
observed in patients with primary focal 
segmental glomerulosclerosis. 4 
 Th e mechanisms by which obesity pre-
disposes people to kidney damage are 
unknown. Hall  et al. reported that obesity 
increases renal sodium reabsorption and 
impairs pressure natriuresis by the activa-
tion of the renin – angiotensin system and 
the sympathetic nervous system and 
by altered intrarenal physical forces. 5 Fur-
ther, insulin resistance in obese subjects 
was associated with a higher glomerular 
filtration fraction. A greater degree of 
insulin resistance may cause renal injury 
by worsening renal hemodynamics 
through elevation of the glomerular fi ltra-
tion fraction and resultant glomerular 
hyperfi ltration. 6 AGE – RAGE interaction 
may also contribute to the pathogenesis of 
obesity-related renal dysfunction. In an 
animal model, a high-fat diet was associ-
ated with obesity and with elevated serum 
and tissue AGEs, nuclear  O -Glc-Nac 
modifi cation, and apoptosis. 7 Moreover, 
AGEs have direct and indirect actions that 
potentially contribute to insulin resistance 
via oxidative stress generation and chronic 
infl ammation. A form of obesity-related 
glomerulosclerosis has been shown 
to develop in animal models of obesity 
such as the fatty Zucker rat. Long-term 
treatment of fatty Zucker rats with piogli-
tazone inhibited diff use or nodular thick-
ening of the mesangial matrix, atrophy of 
the proximal tubules, thickening of the 
basement membrane of the tubules, and 
mild cellular infi ltration in the stroma. 
Furthermore, pioglitazone inhibited 
increased expression of RAGE and trans-
forming growth factor-  mRNA in the 
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